Outsourced Pharma Capacity Update Videos - Large Molecule

  1. Rentschler Biopharma Capabilities Update July 2026: Large Molecule 8/7/2026

    At Rentschler Biopharma, we help biopharma innovators advance complex large molecule programs from development through commercial manufacturing.

  2. Avid Bioservices Capabilities Update July 2026: Large Molecule 8/7/2026

    Discover how integrated development and manufacturing can reduce risk, speed timelines, and support seamless progression from early development to commercial production.

  3. Samsung Biologics Capabilities Update July 2026: Large Molecule 8/6/2026

    We offer end-to-end CDMO services across drug substance, drug product, ADC, mRNA, and organoid modalities, with 845,000L capacity and a 99% batch success rate. Evaluate your multi-plant sourcing framework now.

  4. KBI BioPharma Capabilities Update July 2026: Large Molecule 8/3/2026

    Combining targeted transposon tech with stable bulk pool generation accelerates cell line development, enabling early material production and fast-tracking candidate selection for clinical entry.

  5. AbbVie Capabilities Update July 2026: Large Molecule 8/3/2026

    Integrated manufacturing networks de-risk biopharmaceutical scale-up. Flexible mammalian platforms and advanced ADC conjugation ensure strict quality standards and long-term commercial supply.

  6. Resilience Capabilities Update May 2026: Large Molecule 5/29/2026

    An integrated network unites biologics, cell therapy, and drug product with digital systems and teams to speed tech transfer, scale reliably, and ensure delivery from development to commercial.

  7. Rentschler Biopharma Capabilities Update May 2026: Large Molecule 5/29/2026

    Rentschler Biopharma is a global leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. 

  8. Samsung Biologics Capabilities Update May 2026: Large Molecule 5/28/2026

    Watch this on-demand session to explore the future of global biologics manufacturing, dual-sourcing strategies, and next-generation expansion plans in advanced therapies.

  9. Rezon Bio Capabilities Update May 2026: Large Molecule 5/28/2026

    Discover how tailored biologics development strategies can improve scalability, reduce tech transfer risk, and create more reliable pathways from early development to commercial supply.

  10. Alcami Capabilities Update May 2026: Large Molecule 5/28/2026

    Watch this on-demand session to learn risk-based strategies for optimizing biologic drug substance-to-product transitions while minimizing aggregation and process stress.